CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again

CPHI Barcelona 2023 24 - 26 October, 2023, Barcelona, Spain.
The global pharma industry was out in full force at CPHI Frankfurt in November with 40,405 executives from 167 countries visiting the 2022 edition of the world-leading pharma industry tradeshow, a huge 75% increase over the number of attendees in 2021. Final visitor numbers will be confirmed by independent auditors ABC in early 2023.

The increase in visitor numbers was all the more impressive because many visitors from China - who usually make up around 10% of the show's in person audience - were prevented from attending CPHI Frankfurt by COVID-related travel restrictions. Reflecting the robust strength of the pharma industry, visitor attendance from major markets in Europe and the USA was comparable to the pre-pandemic 2019 event, which was the largest single gathering of pharma executives in CPHI’s thirty-two year history.

CPHI's flagship exhibition is widely regarded as a key bellwether for the pharma industry's prospects for the year ahead, so visitor numbers and other measures of exhibitor and visitor face-to-face and digital interactions are closely monitored.

CPHI's seamless integration of its online and in-person experience has meant the event's digital platform also continued to grow with a record 36,239 online attendees - 49% year-on-year growth - and a staggering 215,580 digital conversations being held, making the 2022 event the largest digital event in CPHI's history.

"The single biggest message coming back from our key stakeholders about CPHI Frankfurt is the exemplary quality of new business meetings they participated in. It's clear pharma partnering rebounded tremendously at this year's event, which bodes extremely well for the industry in 2023. But we have also seen a huge increase in visitors using our digital platform alongside the in-person event to initiate or enhance a 365-day-a-year conversation with their prospects and partners," commented Adam Andersen, Informa’s Executive Vice President, Pharma.

A clear trend evident at this year’s CPHI was the shift toward increasingly senior executives attending the show. The growing number of C-suite executives attend the show to meet their industry peers and to explore the show’s expanded content focused on the latest market innovations and insights for the year ahead. More than 79% of attendees at this year’s show were rated as 'having purchasing power' and 57% at the C-suite level - up from 46% in 2019 - highlighting CPHI Frankfurt's growing significance to the pharma industry's most influential decision-makers.

In parallel with the rebound in visitor numbers, the number of exhibitors at CPHI Frankfurt also compared favourably to the 2019 event, with some 1,846 businesses from 98 countries exhibiting, an increase of nearly 700 on 2021 exhibitor numbers.

The industry is already looking forward to CPHI Barcelona in 2023 to be held at the Fira Barcelona (24 - 26 October 2023). With no travel restrictions expected in 2023, the event is likely to see record numbers of international attendees and exhibitors, especially as global pharma supply networks expand, and outsourcing continues to proliferate. Then in 2024, CPHI Middle East will open for the first time in Riyadh (15-17 January 2024) - creating a new pharma hub for manufacturers and innovators to access this fast-growing pharma region.

Adam Andersen, Informa’s Executive Vice President, Pharma added, "What we have seen throughout CPHI Frankfurt is that our in-person and digital platforms add real-world value and deepen conversations with partners. The event is at the heart of all pharma partnering and, post-pandemic, we have seen many new attendees at the event. For the most part, these new executives are senior pharma industry leaders with specific partnering and supply requirements that they are meeting through CPHI’s online and in person platforms."

About CPHI

CPHI is the leading global community for pharmaceutical professionals, hosting a portfolio of digital and in-person connection opportunities across the whole pharma supply chain. Evolving our events to become part of an integrated digital package means the industry has more time, more flexibility and more opportunities to meet, learn and connect. CPHI is the world's primary pharma event series, with the largest community, and our goal is to proactively inspire the pharma industry to create purposeful partnerships.

At the Heart of Pharma: connecting people and businesses from all over the world. At the heart of pharma, we act as catalysts for industry developments.

For more information, please visit www.informamarkets.com

CPHI China (20 - 22 December 2022 at SNIEC - Shanghai, China); Pharmapack Europe (1 - 2 Feb, 2023 at Paris Expo, Porte de Versailles - Hall 7.2, Paris); CPHI Japan (19 - 21 April, 2023 at the Big Sight Exhibition Centre - Tokyo, Japan); CPHI North America (25 - 27 April, 2023 at Pennsylvania Convention Center, United States), CPHI South East Asia (12 - 14 Jul 2023 at IMPACT, Thailand); CPHI Barcelona (24 - 26 October 2023 at Fira Barcelona, Barcelona).

Most Popular Now

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...